ethyl 2-oxo-2-(4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophen-5-yl)acetate | 14779-31-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 2-oxo-2-(4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophen-5-yl)acetate
• 英文别名: ethyl 2-oxo-2-(4-oxo-6,7-dihydro-5H-1-benzothiophen-5-yl)acetate
• CAS: 14779-31-8
• 化学式: C₁₂H₁₂O₄S
• 分子量: 252.291
• InChiKey: PUKLFORXPXYXIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  88.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-oxo-2-(4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophen-5-yl)acetate 在 sodium hydroxide 、 sodium tetrahydroborate 、 甲酸 、 亚硝酸丁酯 、 sodium ethanolate 、 对甲苯磺酸 、 锌 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 5.0h， 生成 Amino-benzo[b]thiophen-5-yl-acetic acid
  参考文献：
  名称：

  Orally absorbable cephalosporin antibiotics. 2. Structure-activity studies of bicyclic glycine derivatives of 7-aminodeacetoxycephalosporanic acid

  摘要：

  Three positional analogues (4-, 5-, and 7-) of benzothienylglycine and (N-acetylindolinyl)-5-glycine were prepared and coupled to 7-aminodeacetoxycephalosporanic acid (7-ADCA) to give the cephalosporins 17a-c. In addition two isomeric (2,3-b and 3,2-b) thienothiopheneglycines were synthesized and coupled to 7-ADCA to yield cephalosporins 30d and 30e. In vitro testing of these new cephalosporins indicates good activity against Gram-positive bacteria. Against Streptococcus pneumoniae infections compound 25 displayed better mouse protection (both orally and subcutaneously) than cephalexin.

  DOI：

  10.1021/jm00150a023
• 作为产物：
  描述：

  4,5,6,7-四氢-4-苯并噻吩 、 草酸二乙酯 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 以89%的产率得到ethyl 2-oxo-2-(4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophen-5-yl)acetate
  参考文献：
  名称：

  [EN] FUSED DIHYDROINDAZOLE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN
  [FR] DÉRIVÉS DE DIHYDROINDAZOLE FUSIONNÉS AYANT UNE ACTIVITÉ MULTIMODALE CONTRE LA DOULEUR

  摘要：

  本发明涉及具有对α2δ亚基，特别是电压门控钙通道的α2δ亚基具有药理活性的融合二氢吲唑衍生物。它还涉及具有对电压门控钙通道的α2δ亚基，特别是α2δ亚基，以及δ1受体双重药理活性的化合物。本发明还涉及制备这类化合物的方法，包括它们的药物组合物，以及它们在疗法中的使用，特别是用于疼痛治疗。

  公开号：

  WO2020016315A1

文献信息

• [EN] 4,5-DIHYDRO-1H-THIENO[2,3-G]INDAZOLYL DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN<br/>[FR] DÉRIVÉS DE 4,5-DIHYDRO-1H-THIÉNO[2,3-G]INDAZOLYL PRÉSENTANT UNE ACTIVITÉ MULTIMODALE CONTRE LA DOULEUR
  申请人：ESTEVE PHARMACEUTICALS SA

  公开号：WO2019121670A1

  公开（公告）日：2019-06-27

  wherein the meanings for the various substituents are as disclosed in the description, having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ-1 subunit, of the voltage-gated calcium channel and the μ-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

  其中，各种取代基的含义如描述中所披露的，具有对电压门控钙通道的α2δ亚基，特别是α2δ-1亚基，以及μ-阿片受体的双重药理活性，涉及到这些化合物的制备过程，包括含有它们的药物组合物，以及它们在治疗中的应用，特别是用于疼痛治疗。
• Pharmaceutical compounds
  申请人：Neuroscienze Pharmaness S.C. A R.L.

  公开号：EP2230243A1

  公开（公告）日：2010-09-22

  Condensed tricyclic pyrazole compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors, with activity both on the peripheral and central nervous system, of formula (I) : wherein: A represents a group selected from -(CH2)t-, -(CH2)r-O-(CH2)s- and -(CH2)r-S(O)p-(CH2)s- B is an heteroaryl, R is a group selected from heteroaryl, heteroarylalkyl, aryl, arylalkyl, arylalkenyl or bivalent aliphatic chain, R' is a group selected from the following: R'1: a substituent bearing a keto group of formula -C(O)-(Z')v-Z" R'2: a substituent having an hydroxylic function of formula -CH(OH)-(Z')v-Z", R'3: an amide substituent of formula -C(O)-NH-(Z')v-T'.

  具有对CB1和/或CB2大麻素受体亲和力的紧凑三环吡唑化合物，对外周和中枢神经系统均具有活性，其化学式为(I)：其中：A代表从-(CH2)t-, -(CH2)r-O-(CH2)s-和-(CH2)r-S(O)p-(CH2)s-B中选择的基团，B是杂芳基，R是从杂芳基、杂芳烷基、芳基、芳基烷基、芳基烯基或二价脂肪链中选择的基团，R'是从以下选择的基团：R'1：具有化学式-C(O)-(Z')v-Z"的酮基团的取代基，R'2：具有化学式-CH(OH)-(Z')v-Z"的羟基功能的取代基，R'3：具有化学式-C(O)-NH-(Z')v-T'的酰胺取代基。
• PHARMACEUTICAL COMPOUNDS
  申请人：LAZZARI Paolo

  公开号：US20100215759A1

  公开（公告）日：2010-08-26

  Condensed tricyclic pyrazole compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors, with activity both on the peripheral and central nervous system, of formula (I): wherein: A represents a group selected from —(CH 2 ) t —, —(CH 2 ) r —O—(CH 2 ) s — and —(CH 2 ) r —S(O) p —(CH 2 ) s — B is an heteroaryl, R is a group selected from heteroaryl, heteroarylalkyl, aryl, arylalkyl, arylalkenyl or bivalent aliphatic chain, R′ is a group selected from the following: R′ 1 : a substituent bearing a keto group of formula —C(O)— (Z′) v —Z″ R′ 2 : a substituent having an hydroxylic function of formula —CH(OH)—(Z′) v -Z″, R′ 3 : an amide substituent of formula —C(O)—NH—(Z′) v -T′.

  具有对CB1和/或CB2大麻素受体亲和力的紧凑三环吡唑化合物，在外周和中枢神经系统上均具有活性，其化学式为(I)：其中：A代表从—(CH2)t—、—(CH2)r—O—(CH2)s—和—(CH2)r—S(O)p—(CH2)s—中选择的基团，B是杂环烷基，R是从杂环烷基、杂环烷基烷基、芳基、芳基烷基、芳基烯基或二价脂肪链中选择的基团，R′是从以下选择的基团：R′1：具有化学式—C(O)—(Z′)v—Z″的酮基团，R′2：具有化学式—CH(OH)—(Z′)v-Z″的羟基功能的取代基，R′3：具有化学式—C(O)—NH—(Z′)v-T′的酰胺取代基。
• [EN] FUSED DIHYDROINDAZOLE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN<br/>[FR] DÉRIVÉS DE DIHYDROINDAZOLE FUSIONNÉS AYANT UNE ACTIVITÉ MULTIMODALE CONTRE LA DOULEUR
  申请人：ESTEVE PHARMACEUTICALS SA

  公开号：WO2020016315A1

  公开（公告）日：2020-01-23

  The present invention relates to fused dihydroindazole derivatives having pharmacological activity towards the α2δ subunit, in particular the α2δ subunit, of the voltage-gated calcium channel. It also relates to compounds having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ subunit, of the voltage-gated calcium channel and the δ1 receptor. The present invention also relates to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

  本发明涉及具有对α2δ亚基，特别是电压门控钙通道的α2δ亚基具有药理活性的融合二氢吲唑衍生物。它还涉及具有对电压门控钙通道的α2δ亚基，特别是α2δ亚基，以及δ1受体双重药理活性的化合物。本发明还涉及制备这类化合物的方法，包括它们的药物组合物，以及它们在疗法中的使用，特别是用于疼痛治疗。
• Orally absorbable cephalosporin antibiotics. 2. Structure-activity studies of bicyclic glycine derivatives of 7-aminodeacetoxycephalosporanic acid
  作者：Stjepan Kukolja、Susan E. Draheim、Bernard J. Graves、David C. Hunden、Janice L. Pfeil、Robin D. G. Cooper、John L. Ott、Fred T. Counter

  DOI：10.1021/jm00150a023

  日期：1985.12

  Three positional analogues (4-, 5-, and 7-) of benzothienylglycine and (N-acetylindolinyl)-5-glycine were prepared and coupled to 7-aminodeacetoxycephalosporanic acid (7-ADCA) to give the cephalosporins 17a-c. In addition two isomeric (2,3-b and 3,2-b) thienothiopheneglycines were synthesized and coupled to 7-ADCA to yield cephalosporins 30d and 30e. In vitro testing of these new cephalosporins indicates good activity against Gram-positive bacteria. Against Streptococcus pneumoniae infections compound 25 displayed better mouse protection (both orally and subcutaneously) than cephalexin.